INTRODUCTION: Psoriasis is a common skin disease affecting 1% to 3% of the population worldwide. Combination therapy with traditional systemic anti-psoriatic agents offers a promising method for managing severe or recalcitrant psoriasis. AIMS AND OBJECTIVES: Lack of documented data regarding the efficacy and safety of combination therapy with methotrexate and other anti-psoriatic drugs in Iranian patients prompted us to design a study to investigate this issue in an Iranian educational hospital. MATERIALS AND METHODS: Records of psoriatic patients in Razi Hospital were reviewed retrospectively from October 2008 to March 2012. Forty-six patients who had received methotrexate in combination with other systemic anti-psoriatic agents were included in this study. Response to treatment was evaluated by PASI. Adverse reactions and the type of combination were recorded for all patients. RESULTS: Methotrexate was most frequently administered in combination with acitretin (n = 21) followed by cyclosporine (n = 11), and NB-UVB and PUVA (n = 6). Combinations were effective in the majority of patients; 46% showed good response (21 patients), 26% showed moderate response (12 patients) and 28% (13 patients) showed poor response who therefore switched to another treatment. The treatments were generally tolerable. Thirty-two patients experienced adverse events although none was severe or required hospitalization. The relative frequencies of adverse reactions were different among groups of patients receiving various therapeutic regimens. CONCLUSIONS: Methotrexate-combination therapy can offer an effective therapeutic regimen. However, the patients should be monitored for potential adverse effects. More studies are needed to determine the long-term safety and efficacy of these combinations.
INTRODUCTION:Psoriasis is a common skin disease affecting 1% to 3% of the population worldwide. Combination therapy with traditional systemic anti-psoriatic agents offers a promising method for managing severe or recalcitrant psoriasis. AIMS AND OBJECTIVES: Lack of documented data regarding the efficacy and safety of combination therapy with methotrexate and other anti-psoriatic drugs in Iranian patients prompted us to design a study to investigate this issue in an Iranian educational hospital. MATERIALS AND METHODS: Records of psoriatic patients in Razi Hospital were reviewed retrospectively from October 2008 to March 2012. Forty-six patients who had received methotrexate in combination with other systemic anti-psoriatic agents were included in this study. Response to treatment was evaluated by PASI. Adverse reactions and the type of combination were recorded for all patients. RESULTS:Methotrexate was most frequently administered in combination with acitretin (n = 21) followed by cyclosporine (n = 11), and NB-UVB and PUVA (n = 6). Combinations were effective in the majority of patients; 46% showed good response (21 patients), 26% showed moderate response (12 patients) and 28% (13 patients) showed poor response who therefore switched to another treatment. The treatments were generally tolerable. Thirty-two patients experienced adverse events although none was severe or required hospitalization. The relative frequencies of adverse reactions were different among groups of patients receiving various therapeutic regimens. CONCLUSIONS:Methotrexate-combination therapy can offer an effective therapeutic regimen. However, the patients should be monitored for potential adverse effects. More studies are needed to determine the long-term safety and efficacy of these combinations.
Entities:
Keywords:
Combination therapy; methotrexate; psoriasis; responsibility; side effects; systemic non-biologic
Authors: P A Foley; C Quirk; J R Sullivan; C Dolianitis; S P Hack; K Thirunavukkarasu; A J Cooper Journal: J Eur Acad Dermatol Venereol Date: 2010-10 Impact factor: 6.166
Authors: G G Krueger; S R Feldman; C Camisa; M Duvic; J T Elder; A B Gottlieb; J Koo; J G Krueger; M Lebwohl; N Lowe; A Menter; W L Morison; J H Prystowsky; J L Shupack; J R Taylor; G D Weinstein; T L Barton; T Rolstad; R M Day Journal: J Am Acad Dermatol Date: 2000-08 Impact factor: 11.527
Authors: J R Curtis; T Beukelman; A Onofrei; S Cassell; J D Greenberg; A Kavanaugh; G Reed; V Strand; J M Kremer Journal: Ann Rheum Dis Date: 2010-01 Impact factor: 19.103
Authors: Asta Baranauskaite; Helena Raffayová; N V Kungurov; Anna Kubanova; Algirdas Venalis; Laszlo Helmle; Shankar Srinivasan; Evgeny Nasonov; Nathan Vastesaeger Journal: Ann Rheum Dis Date: 2011-10-12 Impact factor: 19.103
Authors: R B Warren; R L Smith; E Campalani; S Eyre; C H Smith; J N W N Barker; J Worthington; C E M Griffiths Journal: Br J Dermatol Date: 2008-10-25 Impact factor: 9.302